The prevalence of Tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders
Autor(a) principal: | |
---|---|
Data de Publicação: | 2004 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://dx.doi.org/10.1007/s00406-004-0514-1 http://repositorio.unifesp.br/handle/11600/43579 |
Resumo: | Aims of the study To assess the impact of olanzapine versus conventional neuroleptic therapy among subjects with schizophrenia on ratings of tardive dyskinesia (TD). Method The naturalistic study was conducted in three psychiatric hospitals in Brazil. Patients had a diagnosis of schizophrenia and related disorders (DSMIV) and with a BPRS score > 24. Patients were evaluated by means of the PANSS scale for symptomatology (Kay et al. 1986), the Clinical Global Impression, The UKU side effect rating scale (Lingjaerde et al. 1987), and the Tardive Dyskinesia AIMS scale (Guy et al. 1976). Patients were seen by the treating physician routinely while hospitalized and then monthly on an out-patient basis. All scale assessments were repeated after 9 months of discharge. Result The sample was comprised of 190 patients (99 in the olanzapine and 91 in the standard treatment), with a completion rate of 88.2 % for olanzapine and 84.9 % for the conventional treatment (p = 0.385, n. s.). The mean change from baseline in the PANSS total score favored olanzapine regarding negative symptoms (2.3, 95% C.I. 0.6-4.1, p<0.001); and general psychopathology (4.0, 95% C.I. 0.8-7.2, p<0.02) factors. TD was defined by applying Morgenstern & Glazer (1993) and Schooler & Kane (1982) criteria, on the basis of the AIMS scale. Both results favored olanzapine at the end of the follow-up (Morgenstern & Glazer: 25.6 % versus 56.3 %; Schooler & Kane: 16.3 % versus 45.2 %). At the end of the follow-up, by using the overall rating of the AIMS scale, the presence of TD was 2.3 % for olanzapine (2/87), and 16.7 % (12/72) for the conventional treatment. Conclusions The results of this open label naturalistic trial showed that olanzapine had an impact on negative symptoms, decreased general psychopathology and reduced the risk of tardive dyskinesia. |
id |
UFSP_53a79843ab963a290bb17f65a9901ffd |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br/:11600/43579 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
The prevalence of Tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disordersschizophreniaTardive dyskinesiarandomized controlled trialolanzapinetypical antipsychoticAims of the study To assess the impact of olanzapine versus conventional neuroleptic therapy among subjects with schizophrenia on ratings of tardive dyskinesia (TD). Method The naturalistic study was conducted in three psychiatric hospitals in Brazil. Patients had a diagnosis of schizophrenia and related disorders (DSMIV) and with a BPRS score > 24. Patients were evaluated by means of the PANSS scale for symptomatology (Kay et al. 1986), the Clinical Global Impression, The UKU side effect rating scale (Lingjaerde et al. 1987), and the Tardive Dyskinesia AIMS scale (Guy et al. 1976). Patients were seen by the treating physician routinely while hospitalized and then monthly on an out-patient basis. All scale assessments were repeated after 9 months of discharge. Result The sample was comprised of 190 patients (99 in the olanzapine and 91 in the standard treatment), with a completion rate of 88.2 % for olanzapine and 84.9 % for the conventional treatment (p = 0.385, n. s.). The mean change from baseline in the PANSS total score favored olanzapine regarding negative symptoms (2.3, 95% C.I. 0.6-4.1, p<0.001); and general psychopathology (4.0, 95% C.I. 0.8-7.2, p<0.02) factors. TD was defined by applying Morgenstern & Glazer (1993) and Schooler & Kane (1982) criteria, on the basis of the AIMS scale. Both results favored olanzapine at the end of the follow-up (Morgenstern & Glazer: 25.6 % versus 56.3 %; Schooler & Kane: 16.3 % versus 45.2 %). At the end of the follow-up, by using the overall rating of the AIMS scale, the presence of TD was 2.3 % for olanzapine (2/87), and 16.7 % (12/72) for the conventional treatment. Conclusions The results of this open label naturalistic trial showed that olanzapine had an impact on negative symptoms, decreased general psychopathology and reduced the risk of tardive dyskinesia.Univ Fed Sao Paulo, Dept Psiquiatria, BR-04023900 Sao Paulo, BrazilFed Univ Pelotas, Dept Psychiat, Eli Lilly, BrazilCatholic Univ Pelotas, Eli Lilly, BrazilHosp Anna Rech, Rio Grande Do Sul, BrazilPax Clin Psiquiatrica Goiania, Goias, BrazilUniv Fed Bahia, Dept Neuropsychiat & Neurol, BR-41170290 Salvador, BA, BrazilUniv Fed Sao Paulo, Dept Psiquiatria, BR-04023900 Sao Paulo, BrazilWeb of ScienceDr Dietrich Steinkopff VerlagUniversidade Federal de São Paulo (UNIFESP)Fed Univ PelotasCatholic Univ PelotasHosp Anna RechPax Clin Psiquiatrica GoianiaUniversidade Federal da Bahia (UFBA)Mari, Jair de Jesus [UNIFESP]Lima, Mauricio Silva de [UNIFESP]Costa, Anna Maria Niccolai [UNIFESP]Alexandrino, NeusaRodrigues-Filho, SalomaoOliveira, Irismar Reis deTollefson, Gary D.2018-06-15T17:17:33Z2018-06-15T17:17:33Z2004-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion356-361http://dx.doi.org/10.1007/s00406-004-0514-1European Archives Of Psychiatry And Clinical Neuroscience. Darmstadt: Dr Dietrich Steinkopff Verlag, v. 254, n. 6, p. 356-361, 2004.10.1007/s00406-004-0514-10940-1334http://repositorio.unifesp.br/handle/11600/43579WOS:000226092900002engEuropean Archives Of Psychiatry And Clinical Neuroscienceinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-05-02T13:59:21Zoai:repositorio.unifesp.br/:11600/43579Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-05-02T13:59:21Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.none.fl_str_mv |
The prevalence of Tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders |
title |
The prevalence of Tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders |
spellingShingle |
The prevalence of Tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders Mari, Jair de Jesus [UNIFESP] schizophrenia Tardive dyskinesia randomized controlled trial olanzapine typical antipsychotic |
title_short |
The prevalence of Tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders |
title_full |
The prevalence of Tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders |
title_fullStr |
The prevalence of Tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders |
title_full_unstemmed |
The prevalence of Tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders |
title_sort |
The prevalence of Tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders |
author |
Mari, Jair de Jesus [UNIFESP] |
author_facet |
Mari, Jair de Jesus [UNIFESP] Lima, Mauricio Silva de [UNIFESP] Costa, Anna Maria Niccolai [UNIFESP] Alexandrino, Neusa Rodrigues-Filho, Salomao Oliveira, Irismar Reis de Tollefson, Gary D. |
author_role |
author |
author2 |
Lima, Mauricio Silva de [UNIFESP] Costa, Anna Maria Niccolai [UNIFESP] Alexandrino, Neusa Rodrigues-Filho, Salomao Oliveira, Irismar Reis de Tollefson, Gary D. |
author2_role |
author author author author author author |
dc.contributor.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) Fed Univ Pelotas Catholic Univ Pelotas Hosp Anna Rech Pax Clin Psiquiatrica Goiania Universidade Federal da Bahia (UFBA) |
dc.contributor.author.fl_str_mv |
Mari, Jair de Jesus [UNIFESP] Lima, Mauricio Silva de [UNIFESP] Costa, Anna Maria Niccolai [UNIFESP] Alexandrino, Neusa Rodrigues-Filho, Salomao Oliveira, Irismar Reis de Tollefson, Gary D. |
dc.subject.por.fl_str_mv |
schizophrenia Tardive dyskinesia randomized controlled trial olanzapine typical antipsychotic |
topic |
schizophrenia Tardive dyskinesia randomized controlled trial olanzapine typical antipsychotic |
description |
Aims of the study To assess the impact of olanzapine versus conventional neuroleptic therapy among subjects with schizophrenia on ratings of tardive dyskinesia (TD). Method The naturalistic study was conducted in three psychiatric hospitals in Brazil. Patients had a diagnosis of schizophrenia and related disorders (DSMIV) and with a BPRS score > 24. Patients were evaluated by means of the PANSS scale for symptomatology (Kay et al. 1986), the Clinical Global Impression, The UKU side effect rating scale (Lingjaerde et al. 1987), and the Tardive Dyskinesia AIMS scale (Guy et al. 1976). Patients were seen by the treating physician routinely while hospitalized and then monthly on an out-patient basis. All scale assessments were repeated after 9 months of discharge. Result The sample was comprised of 190 patients (99 in the olanzapine and 91 in the standard treatment), with a completion rate of 88.2 % for olanzapine and 84.9 % for the conventional treatment (p = 0.385, n. s.). The mean change from baseline in the PANSS total score favored olanzapine regarding negative symptoms (2.3, 95% C.I. 0.6-4.1, p<0.001); and general psychopathology (4.0, 95% C.I. 0.8-7.2, p<0.02) factors. TD was defined by applying Morgenstern & Glazer (1993) and Schooler & Kane (1982) criteria, on the basis of the AIMS scale. Both results favored olanzapine at the end of the follow-up (Morgenstern & Glazer: 25.6 % versus 56.3 %; Schooler & Kane: 16.3 % versus 45.2 %). At the end of the follow-up, by using the overall rating of the AIMS scale, the presence of TD was 2.3 % for olanzapine (2/87), and 16.7 % (12/72) for the conventional treatment. Conclusions The results of this open label naturalistic trial showed that olanzapine had an impact on negative symptoms, decreased general psychopathology and reduced the risk of tardive dyskinesia. |
publishDate |
2004 |
dc.date.none.fl_str_mv |
2004-12-01 2018-06-15T17:17:33Z 2018-06-15T17:17:33Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1007/s00406-004-0514-1 European Archives Of Psychiatry And Clinical Neuroscience. Darmstadt: Dr Dietrich Steinkopff Verlag, v. 254, n. 6, p. 356-361, 2004. 10.1007/s00406-004-0514-1 0940-1334 http://repositorio.unifesp.br/handle/11600/43579 WOS:000226092900002 |
url |
http://dx.doi.org/10.1007/s00406-004-0514-1 http://repositorio.unifesp.br/handle/11600/43579 |
identifier_str_mv |
European Archives Of Psychiatry And Clinical Neuroscience. Darmstadt: Dr Dietrich Steinkopff Verlag, v. 254, n. 6, p. 356-361, 2004. 10.1007/s00406-004-0514-1 0940-1334 WOS:000226092900002 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
European Archives Of Psychiatry And Clinical Neuroscience |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
356-361 |
dc.publisher.none.fl_str_mv |
Dr Dietrich Steinkopff Verlag |
publisher.none.fl_str_mv |
Dr Dietrich Steinkopff Verlag |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
biblioteca.csp@unifesp.br |
_version_ |
1814268279932321792 |